The use of PET in Parkinson's disease.
Activation studies with positron emission tomography (PET) have provided an understanding of the pathophysiology of akinesia and tremor in Parkinson's disease (PD). [18F]6-fluoro-L-dopa (FD)-PET and dopamine receptor imaging by PET can assist in the differential diagnosis of various forms of parkinsonism. FED-PET is capable of detecting subclinical dopaminergic deficits. This allows not only the early or preclinical detection of PD but also the investigation of subclinical lesions of the substantia nigra in PD-related disorders. Longitudinal studies of PD and MPTP induced parkinsonism have provided new insight into the pathogenesis of PD.
Shinotoh
H
H
Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.
Calne
D B
DB
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000627:therapeutic use; D000375:Aging; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001665:Binding Sites; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000503:physiopathology; D003342:Corpus Striatum / Q000503:physiopathology; D003937:Diagnosis, Differential; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology; D010300:Parkinson Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology*; D017448:Receptors, Dopamine D2 / Q000502:physiology; D013378:Substantia Nigra / Q000503:physiopathology*; D014055:Tomography, Emission-Computed
D000978:Antiparkinson Agents; D018377:Neurotransmitter Agents; D017448:Receptors, Dopamine D2; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine